ArticleRespiratory research2021
Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.
Article in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 40 citations in OpenAlex.
- Epidemiology, risk factors and clinical outcomes of multidrug-resistantJournal of thoracic disease · 2026Article
- Analysis of clinical characteristics and bronchoalveolar lavage fluid microbial community diversity in non-cystic fibrosis bronchiectasis patients withMicrobiology spectrum · 2026Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Antibiotic pressure does not uncover intra-host heterogeneity of Pseudomonas aeruginosa in patients with chronic lung disease.BMC microbiology · 2026Observational
- Pseudomonas aeruginosa phenotypes associated with radiological severity in non-cystic fibrosis bronchiectasis.BMC pulmonary medicine · 2026Article
- Clinical and prognostic characteristics of stable bronchiectasis in adults with chronic Pseudomonas aeruginosa infection: a prospective cohort study.BMC pulmonary medicine · 2026Article
- Genomic diversity and adaptive resistance mechanisms inmSystems · 2026Article
- Therapies for bronchiectasis: mechanisms and potential effects.Frontiers in immunology · 2026Review
- Secondary infections following tuberculosis: epidemiology, pathogenesis and clinical implications.Breathe (Sheffield, England) · 2026Review
- Validation of Bronchiectasis Health Questionnaire (BHQ) in Chinese Patients With Noncystic Fibrosis Bronchiectasis.Canadian respiratory journal · 2026Article
- Factors governing the response ofFrontiers in cellular and infection microbiology · 2026Review
- Bacteria-phage infection network structure and genomic defence system content predict efficacy of a phage therapy cocktail againstPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Comparative efficacy and safety of inhaled antibiotics in managing chronicJournal of thoracic disease · 2025Article
- Clinical Implications ofChronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Relation between vitamin D deficiency and Pseudomonas aeruginosa colonization in patients with bronchiectasis.BMC pulmonary medicine · 2025Article
- Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery embolization.Frontiers in medicine · 2025Article
- Cost-effectiveness analysis of two inhaled antibiotics for stable Bronchiectasis with Pseudomonas aeruginosa infections in China.PloS one · 2025Article
- Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes-Results From a Large Territory-Wide Cohort Study.The clinical respiratory journal · 2025Article
- Bacterial products initiation of alpha-synuclein pathology: an in vitro study.Scientific reports · 2024Article
- Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa is one of the commonest bacteria colonizing the airway in patients with non-cystic fibrosis bronchiectasis. Pseudomonas aeruginosa colonization is associated with poor outcomes in patients with bronchiectasis, including rapid decline in lung function, exacerbation frequency and hospitalization.
methodsA cross-sectional study in Queen Mary Hospital, Hong Kong that included 350 Chinese patients with non-cystic fibrosis bronchiectasis to investigate the risk factors for Pseudomonas aeruginosa colonization and clinical implications on disease outcomes. DISCUSSIONS: Pseudomonas aeruginosa colonization was more commonly found in patients with longer duration of bronchiectasis and those on proton pump inhibitors (PPIs) with adjusted ORs of 1.066 (95% CI = 1.036-1.096, p < 0.001) and 2.815 (95% CI = 1.307-6.064, p = 0.008) respectively. Patients with Pseudomonas aeruginosa colonization have more extensive lung involvement and higher risks of exacerbation requiring hospitalization with adjusted ORs of 2.445 (95% CI = 1.283-4.657, p = 0.007) and 2.745 (95% CI = 1.012-7.449, p = 0.047) respectively. Pseudomonas aeruginosa colonization is more common among patients with longer duration of bronchiectasis and those on PPI. Pseudomonas aeruginosa colonization is associated with more extensive lung involvement and higher risks of exacerbation requiring hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.